Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
32 hedge funds and large institutions have $264M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 10 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
31% more capital invested
Capital invested by funds: $202M → $264M (+$62.1M)
7% more funds holding
Funds holding: 30 → 32 (+2)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.81M |
| 2 |
BlackRock
New York
|
+$1.47M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.19M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$917K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$840K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.62M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$3.01M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$938K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$911K |
| 5 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$533K |
STSA Hedge Fund Activity: Q4 2019 in Review
32 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q4 2019, worth a combined $264M — up 31% from $202M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new STSA positions and 10 closed out — a net gain of 7 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.81M. The largest seller was Credit Suisse, cutting an estimated $3.62M.
- 32 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q4 2019, up from 30 in Q3 2019.
- Funds reported $264M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q4 2019, up 31% quarter-over-quarter.
- 17 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 10 closed out, a net change of +7 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was Vanguard Group, an estimated $3.81M added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Credit Suisse, an estimated $3.62M sold.
Based on aggregated 13F filings for Q4 2019.